RELMADA THERAPEUTICS, INC. License Costs (Deprecated 2018-01-31)
RELMADA THERAPEUTICS, INC. (RLMD) reported License Costs (Deprecated 2018-01-31) of $16.62 thousand for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LicenseCosts · last filed 2017-09-28
- RELMADA THERAPEUTICS, INC. license costs (deprecated 2018-01-31) for the quarter ending 2016-06-30 was $0.00.
- RELMADA THERAPEUTICS, INC. license costs (deprecated 2018-01-31) for fiscal 2017 was $16.62K, a 0.00% change from fiscal 2016.
- RELMADA THERAPEUTICS, INC. license costs (deprecated 2018-01-31) for fiscal 2016 was $16.62K.
| Period end | License Costs (Deprecated 2018-01-31) 3 month | License Costs (Deprecated 2018-01-31) 9 month | License Costs (Deprecated 2018-01-31) 12 month |
|---|---|---|---|
| 2017-06-30 | $16.62K 10-K · filed 2017-09-28 | ||
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | $16.62K 10-K · filed 2016-09-09 | |
| 2016-03-31 | $16.62K 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |